Ocular hypertension

Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results

Retrieved on: 
星期一, 四月 22, 2024
Poster, Marshal of France, International, Drug, Bausch & Lomb, Research, Depreciation, Mass meeting, Sale, NCX, IOP, Kowa, ARVO, Patent, Patient, COVID-19, Nitric oxide, Ocular hypertension, Glaucoma, BlackRock, Pharmaceutical industry

“Nicox made good progress in 2023 as we move towards topline results of the Denali Phase 3 trial which we expect in H2 2025.

Key Points: 
  • “Nicox made good progress in 2023 as we move towards topline results of the Denali Phase 3 trial which we expect in H2 2025.
  • The Nicox Board of Directors has co-opted Dr Gavin Spencer, CEO of Nicox, as a Board member with effect from April 8, 2024.
  • The debt restructuring amendment which was agreed in principle between Nicox and BlackRock and announced on February 28, 2024 was signed.
  • The audit procedures on the 2023 statutory financial statements of Nicox SA have been completed and the certification report is in the process of being issued.

Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class Iop-lowering Drug Candidate for Glaucoma

Retrieved on: 
星期二, 四月 30, 2024
Biotechnology, General Health, Health, Clinical Trials, Mayo Clinic, Osprey, Safety, EVP, Biochemistry, IOP, OHT, Hyperaemia, Therapy, Intraocular pressure, Patient, Trabecular meshwork, Ocular hypertension, General partnership, NTG, MBA, OAG, Molecular biology, Glaucoma, Ophthalmology, Overalls, Pharmaceutical industry

Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round.

Key Points: 
  • Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round.
  • Proceeds from the financing will support the continued clinical development of QLS‑111, a first-in-class therapeutic being developed to lower intraocular pressure (IOP) by targeting episcleral venous pressure (EVP).
  • “Qlaris is dedicated to developing new mechanisms of action that target unaddressed parameters within IOP regulation, an area of critical need.
  • Qlaris has the potential to demonstrate the importance of targeting EVP in the ongoing QLS‑111 Phase II trials and we look forward to the data from this innovative drug candidate.”

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Retrieved on: 
星期六, 四月 6, 2024
IOP, Glaucoma, Conditional sentence, Ocular hypertension, Endothelium, Arm, Medicine, Safety, Risk, ASCRS, Patient, Protocol, MD, Genetically modified bacteria, Science, Intraocular pressure, Travoprost, FDA

BEDFORD, Mass., April 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced positive Phase 2 data for PAXTRAVA (travoprost intracameral implant or OTX-TIC) in patients with open-angle glaucoma or ocular hypertension (reported together as “glaucoma”, below) The data are being presented by Mark Gallardo, MD during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.

Key Points: 
  • “Ocular is very pleased to report positive six-month topline results for PAXTRAVA in the Phase 2 glaucoma study.
  • We designed the Phase 2 clinical trial to evaluate PAXTRAVA over several time points that we believe are clinically meaningful, through six months.
  • Most ocular AEs within 3 days were deemed related to the injection procedure by the investigators.
  • I am enthusiastic about PAXTRAVA because of the positive, durable IOP reductions, accompanied by a good overall safety profile,” said Mark Gallardo, MD.

SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma

Retrieved on: 
星期二, 四月 2, 2024
IOP, Bimatoprost, Glaucoma, Ocular hypertension, Pressure, IOL, ASCRS, Patient, Tissue, Cataract, Month, Spyglass, Visual acuity, Society, Safety, IOPS, Therapy, FDA, Intraocular pressure, Annual general meeting, Pharmaceutical industry

ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation during the American Society of Cataract and Refractive Surgeons (ASCRS) Annual Meeting, held from April 5-8 in Boston.

Key Points: 
  • ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery.
  • The SpyGlass platform was well tolerated and there were no adverse events related to the product.
  • These data highlight the substantial potential of the SpyGlass Drug Delivery Platform to be a game changer for patients and all cataract surgeons.”
    “SpyGlass technology has the potential to change the paradigm and improve care for glaucoma patients undergoing routine cataract surgery,” said Patrick Mooney, CEO, SpyGlass PharmaTM.
  • The compelling clinical data released this week suggest we are on track to bringing our innovative platform to patients.”
    The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver 3 years of bimatoprost to targeted tissues.

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

Retrieved on: 
星期二, 三月 26, 2024
Incidence, Ocular hypertension, Refractive surgery, ASCRS, Diabetic retinopathy, Patient, IRIS, Cataract, Quality of life, Eye, Society, Annual general meeting

BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple scientific presentations at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 5-8 in Boston, Massachusetts.

Key Points: 
  • BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple scientific presentations at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 5-8 in Boston, Massachusetts.
  • Title: Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: Results from a Phase 2 Clinical Trial
    Title: Incidence of Safety Events Following Cataract Surgery with Intracanalicular Dexamethasone: A Study of 50,000 Eyes Using the IRIS Registry
    Title: Characteristics of Cataract Surgery Patients Receiving Intracanalicular Dexamethasone Insert: An IRIS Registry Analysis of 50,000 Eyes

Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology

Retrieved on: 
星期三, 三月 20, 2024
IOP, Ocular hypertension, Professor, NCX, Patient, American Journal, American Journal of Ophthalmology, Glaucoma, Vision science, Intraocular pressure, Pharmaceutical industry

Topline results from second Phase 3 trial of NCX 470, Denali, expected in H2 2025

Key Points: 
  • Topline results from second Phase 3 trial of NCX 470, Denali, expected in H2 2025
    Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost in the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension have been published in the peer-reviewed journal American Journal of Ophthalmology.
  • “The data from the Mont Blanc Phase 3 trial demonstrated the potential of NCX 470 and we look forward to seeing confirmation of this clinical profile in the upcoming results from the ongoing Denali Phase 3 trial, expected in H2 2025.
  • The Mont Blanc publication concludes that “The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with open-angle glaucoma or ocular hypertension at all 6 time points.
  • With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma.”

Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024

Retrieved on: 
星期三, 三月 13, 2024
Mont Blanc, IOP, OCT, Whistler, Glaucoma, Ocular hypertension, Fluticasone, Database, Intraocular pressure, NCX, COVID-19, Patient, NDA, BlackRock, Sale, Bausch & Lomb, Therapy, Retina, Allergic conjunctivitis, Safety, Patent, Telecanthus, FDA, Corporation, Food, Pharmaceutical industry

“Nicox is focusing its resources on the Denali Phase 3 pivotal trial of its lead asset NCX 470 in glaucoma.

Key Points: 
  • “Nicox is focusing its resources on the Denali Phase 3 pivotal trial of its lead asset NCX 470 in glaucoma.
  • We are reducing costs, including the size of the organization, and are exploring advancing NCX 1728, through collaborations.
  • In January 2024, Nicox expanded the territory of the exclusive licensing agreement with Harrow, Inc., to include Canada.
  • The Company is financed to at least November 2024, based on focusing exclusively on the development of NCX 470.

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Retrieved on: 
星期三, 四月 3, 2024
Medical Devices, Surgery, Health Technology, Health Insurance, Biotechnology, Managed Care, General Health, Pharmaceutical, Health, Optical, Retina, IOP, HCPCS, Glaucoma, Ocular hypertension, OAG, OHT, Patient, Corporation, APC, Eye, Surgeon, CPT, Travoprost, GKOS, OPPS, Idose, Medicare, CMS, Government, Intraocular pressure

The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.

Key Points: 
  • The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.
  • It is expected to increase patient access in the U.S. and has been published here on the CMS website.
  • “The receipt of a product-specific J-code for iDose TR supports our market access initiatives to enable broad access and coverage for patients suffering from open-angle glaucoma or ocular hypertension,” said Thomas Burns, Glaukos chairman and chief executive officer.
  • iDose TR is intended to improve the standard of care by addressing the ubiquitous patient non-compliance issues and chronic side effects associated with topical glaucoma medications.

Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase II Trials

Retrieved on: 
星期二, 四月 2, 2024
Health, Clinical Trials, Research, Science, Optical, Biotechnology, IOP, Kiwi (bird), Ocular hypertension, OAG, Glaucoma, Pressure, EVP, OHT, NTG, Patient, Ageing, Hyperaemia, Humour, Latanoprost, ATP, Safety, Pharmaceutical industry

Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate U.S.

Key Points: 
  • Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate U.S.
  • Phase II masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma.
  • “The start of these Phase II trials represents a key milestone in our goal of bringing QLS‑111 to glaucoma patients for whom consistent IOP lowering and control has been an unachievable goal,” said Thurein Htoo, Chief Executive Officer.
  • “IOP remains the only modifiable risk factor for the treatment of glaucoma, and additional treatments are needed for patients.

Center For Sight Implants New FDA-Approved iDose®TR Device

Retrieved on: 
星期二, 三月 26, 2024
Surgery, Medical Devices, FDA, Hospitals, Biotechnology, Other Health, Health, General Health, Optical, Optic nerve, Ocular hypertension, Paratriathlon, Patient, Cataract, Eye, Multimedia, Intraocular pressure, Food, Medical device

The iDoseTR implant, manufactured by Glaukos Corporation, is a sustained release ophthalmic implant that is surgically placed in the eye.

Key Points: 
  • The iDoseTR implant, manufactured by Glaukos Corporation, is a sustained release ophthalmic implant that is surgically placed in the eye.
  • The device consistently distributes a travoprost formula to help reduce intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
  • is a member of the US Eye Physician Advisory Board and is a Cataract and Glaucoma Surgeon at Center For Sight.
  • Speaking of the device, he shares, “We found the device and medication formula to work very well in our study patients.